Navigation Links
Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
Date:3/17/2008

spending on preclinical and clinical development of the Company's product candidates, internal research efforts, manufacturing development efforts, personnel related costs to support these efforts and costs related to infrastructure to

support operating as a public company for the full period as well as increased share-based compensation costs.

Alexza ended the year with consolidated cash, cash equivalents and marketable securities of $108.8 million, including $39.4 million of marketable securities held by Symphony Allegro.

On January 1, 2006, Alexza adopted FAS 123R and reports employee share- based compensation expense based on the fair value of the award. Share-based compensation was $1,378,000 in the fourth quarter of 2007 and $3,416,000 in the year ended December 31, 2007 as compared to $810,000 and $2,217,000 in the comparable periods in 2006.

Alexza's Consolidated Statements of Operations include the operations of Symphony Allegro, Inc. "Loss attributed to noncontrolling interest in Symphony Allegro, Inc." reduced net loss for the fourth quarter of 2007 by $3.1 million and by $10.8 million for the year ended December 31, 2007. The transaction with Symphony Allegro was completed in December 2006 and reduced net loss by $1.7 million in both the fourth quarter and year ended December 31, 2006.

Excluding non-cash share-based compensation expense, non-GAAP net loss was $11.8 million for the fourth quarter of 2007 and $41.7 million for the year ended December 31, 2007 as compared to $10.8 million and $39.6 million in the comparable periods in 2006.

Note: Alexza's non-GAAP net loss excludes non-cash share-based compensation expense. The differences in non-GAAP and GAAP numbers are reconciled in the tables below (in thousands):

Three Months Ended

December 31,


'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Spherix Reports Second Quarter Earnings
6. Tapestry Reports Second Quarter 2007 Results
7. Callisto Reports on Second-Quarter 2007 Milestones
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014 Research and Markets ... the "Investment Analysis of the US Medical ... http://photos.prnewswire.com/prnh/20130307/600769 ... medical device sector identifies the key trends and ... investments, and mergers and acquisitions. The ...
(Date:12/22/2014)... , Dec. 22, 2014 Swedish Orphan ... today announced that the Committee for Medicinal Products for ... has adopted a positive opinion for the use of ... men with Peyronie,s disease with a palpable plaque and ... start of therapy. The use of Xiapex ...
(Date:12/22/2014)... 2014  Eiger BioPharmaceuticals Incorporated announced the positive ... in patients with chronic hepatitis delta virus (HDV) ... Institutes of Health (NIH) Clinical Center in ... placebo-controlled, dose ascending study evaluated two doses of ... twice daily for 28 days.  "This proof-of-concept study ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... Fla., Dec. 1, 2011  Hybrid Fuels, Inc. (Pink Sheets: ... acquired 100% of the shares of EMG Marketing Solutions, ... sales, marketing and product development expertise to the multi-billion ... a wholly owned subsidiary of Hybrid Fuels. ...
... 2011 HASCO Medical, Inc. (OTCBB: HASC), www.mysouthernmed.com ... serves patients in Alabama, Florida, and Mississippi, announced today ... Ocala, Florida. The acquisition closed on November 16, 2011. ... supplier that has been located in the Ocala, Florida ...
Cached Medicine Technology:Hybrid Fuels, Inc. Acquires Marketing Company Focused on Multi-Billion Dollar Nutraceutical/Pharmaceutical Industry 2HASCO Medical Announces Approval to Acquire Certified Medical and Certified Auto of Ocala 2HASCO Medical Announces Approval to Acquire Certified Medical and Certified Auto of Ocala 3
(Date:12/26/2014)... (PRWEB) December 26, 2014 Cooking ... of 3.1 out of 5. This score reflects slightly ... level of product specialization, low switching costs and a ... reduced by the low availability of substitutes for cooking ... price of steel and aluminum, key inputs in the ...
(Date:12/26/2014)... December 26, 2014 “Many people become ... personal injury claim issues and phone calls with insurance ... an article featuring their free eBook on pedestrian ... eBook on pedestrian and bicycle auto accident claims assures ... fully capable of professionally handling their case while they ...
(Date:12/26/2014)... (PRWEB) December 26, 2014 Parker ... for the best in heating, cooling and plumbing ... 24 hour emergency services in 2014 with regard ... know that Arizona is known for its incredibly ... that understands the intricacies and details of a ...
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) ... on the current treatment landscape, unmet needs, current ... market. Stivarga is a drug which is used ... Boehringer Ingelheim is developing nintedanib (BIBF-1120), an orally ... CRC in the US, Europe, and Japan. The ...
(Date:12/25/2014)... 26, 2014 Recently, iFitDress.com, the popular online ... has announced its new selection of black one-shoulder cocktail ... sale now; they are available at discounted prices, up to ... promotion will last for three weeks only. You know, we ... who are interested in our new items can visit our ...
Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2
... report published in the January/February issue of General Dentistry, ... says that most children's medicines have the potential to ... in them. // ,For example, antihistamine syrups contain ... pH levels, which mean that they are high in ...
... alcohol dependence is greatly increased if an individual has a ... on the tongue // . The taste receptor gene, called ... at the Washington University School of Medicine have studied more ... of the family participated in a study called Collaborative Study ...
... very little precautionary measures can be taken to actually prevent ... infection in humans is actually caused by the H5N1 strain ... global pandemic it has issued various guidelines which will reduce ... The government says that as such there is no vaccine ...
... Australian Health Minister Tony Abbott told the press that all the ... they consulted qualified health care // personnels. ,This ... rural areas. But in a period of six months this plan ... ,This plan will help in reducing the amount of expenditure ...
... Museum in London has found a unique way to help people ... the much-needed dose of light // . ,The Dana ... dark winter days. ,Up to 500,000 people, a majority ... affective disorder. SAD is more common in the northern latitudes ...
... The worldwide scare of bird flu pandemic as increased which ... bird flu drug by many countries//. U.S. has stocked more ... producing the generic version of the drug Tamiflu manufactured by ... rush for shikimic acid which is used for production of ...
Cached Medicine News:Health News:Genetic Variation In Bitter-Taste Receptor Gene Increases Alcoholic Risk 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: